Li J Yu
Overview
Explore the profile of Li J Yu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
284
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bouhaddou M, Yu L, Lunardi S, Stamatelos S, Mack F, Gallo J, et al.
Clin Transl Sci
. 2019 Nov;
13(2):419-429.
PMID: 31729169
Reliably predicting in vivo efficacy from in vitro data would facilitate drug development by reducing animal usage and guiding drug dosing in human clinical trials. However, such prediction remains challenging....
2.
Parrott N, Yu L, Takano R, Nakamura M, Morcos P
AAPS J
. 2016 Jul;
18(6):1464-1474.
PMID: 27450228
Alectinib, a lipophilic, basic, anaplastic lymphoma kinase (ALK) inhibitor with very low aqueous solubility, has received Food and Drug Administration-accelerated approval for the treatment of patients with ALK+ non-small-cell lung...
3.
Glenn K, Yu L, Reddy M, Fretland A, Parrott N, Hussain S, et al.
Xenobiotica
. 2015 Nov;
46(8):667-76.
PMID: 26586447
1. Idasanutlin (RG7388) is a potent p53-MDM2 antagonist currently in clinical development for treatment of cancer. The purpose of the present studies was to investigate the cause of marked decrease...
4.
Yoo E, Yu L, Wims L, Goldberg D, Morrison S
MAbs
. 2010 May;
2(3):320-34.
PMID: 20431350
The development and production of recombinant monoclonal antibodies is well established. Although most of these are IgGs, there is also great interest in producing recombinant IgAs since this isotype plays...
5.
Deninno M, Andrews M, Bell A, Chen Y, Eller-Zarbo C, Eshelby N, et al.
Bioorg Med Chem Lett
. 2009 Apr;
19(9):2537-41.
PMID: 19339180
Starting from a non-selective pyrazolo-pyrimidone lead, the sequential use of parallel medicinal chemistry and directed synthesis led to the discovery of potent, highly selective, and orally bioavailable PDE9 inhibitors. The...
6.
Cannons J, Yu L, Jankovic D, Crotty S, Horai R, Kirby M, et al.
J Exp Med
. 2006 Jun;
203(6):1551-65.
PMID: 16754717
X-linked lymphoproliferative disease is caused by mutations affecting SH2D1A/SAP, an adaptor that recruits Fyn to signal lymphocyte activation molecule (SLAM)-related receptors. After infection, SLAM-associated protein (SAP)-/- mice show increased T...
7.
Yu L, Chen Y, Treadway J, McPherson R, McCoid S, Gibbs E, et al.
J Pharmacol Exp Ther
. 2006 Mar;
317(3):1230-7.
PMID: 16537796
In drug discovery, establishing a correlation between in vitro potency and in vivo activity is critical for the validation of the selected target and for developing confidence in the in...
8.
Hop C, Chen Y, Yu L
Rapid Commun Mass Spectrom
. 2005 Oct;
19(21):3139-42.
PMID: 16206125
The major drawback of liquid chromatography/mass spectrometry (LC/MS) for the analysis of mixtures is the non-quantitative nature of these studies. The ionization efficiency of the various components in the mixture...
9.
Yu L, Chen Y, Deninno M, OConnell T, Hop C
Drug Metab Dispos
. 2005 Jan;
33(4):484-8.
PMID: 15640374
Clinical use of the nonsteroidal anti-inflammatory drug diclofenac (DF) is associated with an incidence of idiosyncratic hepatoxicity. The formation of reactive metabolites of DF in vivo has been proposed to...
10.
Cannons J, Yu L, Hill B, Mijares L, Dombroski D, Nichols K, et al.
Immunity
. 2004 Nov;
21(5):693-706.
PMID: 15539155
XLP is caused by mutations affecting SAP, an adaptor that recruits Fyn to SLAM family receptors. SAP-deficient mice recapitulate features of XLP, including increased T cell activation and decreased humoral...